Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveThis study aimed to investigate the potential predictive factors for platinum resistance and poor prognosis inepithelial ovarian, fallopian tube, and primary peritoneal cancer treated with platinum-based chemotherapy. MethodsMedical records of 306 patients with the above mentioned cancers treated with platinum-based chemotherapybetween 2007 and 2017 were retrospective reviewed. Clinical data, preoperative neutrophil-to-lymphocyte ratio (NLR),platelet-to-lymphocyte ratio (PLR), platinum-free interval, and survival time were recorded. NLR, PLR, and cancerantigen 125 (CA125) levels were calculated for an optimal cutoff point using receiver operating characteristic curves. The clinicopathological variables were compared using univariate and multivariate analyses to identify independentpredictive factors for platinum resistance and poor survival outcomes. ResultsThe optimal cutoff points for NLR, PLR, and CA125 were 3.38, 210, and 365 IU/L, respectively. Univariate analysisindicated that NLR >3.38, PLR >210, CA125 >365, advanced stage, suboptimal disease, serous type, and ascites weresignificant predictive factors for platinum resistance. However, only NLR >3.38 and advanced stage were independentpredictive factors with an adjusted odds ratio of 1.880 and 3.333, respectively. Regarding factors associated with poorsurvival outcomes, only PLR >210 and advanced stage were independent factors, with a hazard ratio of 1.578 and 3.994,respectively. ConclusionHigh NLR and advanced stage were potential independent predictive factors for platinum resistance, whereas highPLR and advanced stage were potential independent predictive factors for poor survival outcomes.
Abstract
ObjectiveThis study aimed to investigate the potential predictive factors for platinum resistance and poor prognosis inepithelial ovarian, fallopian tube, and primary peritoneal cancer treated with platinum-based chemotherapy. MethodsMedical records of 306 patients with the above mentioned cancers treated with platinum-based chemotherapybetween 2007 and 2017 were retrospective reviewed. Clinical data, preoperative neutrophil-to-lymphocyte ratio (NLR),platelet-to-lymphocyte ratio (PLR), platinum-free interval, and survival time were recorded. NLR, PLR, and cancerantigen 125 (CA125) levels were calculated for an optimal cutoff point using receiver operating characteristic curves. The clinicopathological variables were compared using univariate and multivariate analyses to identify independentpredictive factors for platinum resistance and poor survival outcomes. ResultsThe optimal cutoff points for NLR, PLR, and CA125 were 3.38, 210, and 365 IU/L, respectively. Univariate analysisindicated that NLR >3.38, PLR >210, CA125 >365, advanced stage, suboptimal disease, serous type, and ascites weresignificant predictive factors for platinum resistance. However, only NLR >3.38 and advanced stage were independentpredictive factors with an adjusted odds ratio of 1.880 and 3.333, respectively. Regarding factors associated with poorsurvival outcomes, only PLR >210 and advanced stage were independent factors, with a hazard ratio of 1.578 and 3.994,respectively. ConclusionHigh NLR and advanced stage were potential independent predictive factors for platinum resistance, whereas highPLR and advanced stage were potential independent predictive factors for poor survival outcomes.
참고문헌 (14)
- "Estimated number of new cases in 2018, worldwide, females" (2018)[URL]
- Jayson GC, "Ovarian cancer", Lancet, 384, pp.1376~1388 (2014)
- Pignata S, "Treatment of recurrent ovarian cancer", Ann Oncol, 28, pp.viii51~6 (2017)
- Ocana A, "Neutrophils in cancer : prognostic role and therapeutic strategies", Mol Cancer, 16, pp.137~144 (2017)
- Badora-Rybicka A, "Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer", ESMO Open, 1, pp.e000039~ (2016)
- Miao Y, "Prognostic significance of preoperative prognostic nutritional index in epithelial ovarian cancer patients treated with platinum-based chemotherapy", Oncol Res Treat, 39, pp.712~719 (2016)
- Jansaka N, "Survival outcomes of recurrent epithelial ovarian cancer : experience from a Thailand northern tertiary care center", Asian Pac J Cancer Prev, 15, pp.10837~10840 (2014)
- Moses K, "Human neutrophils : their role in cancer and relation to myeloid-derived suppressor cells", Semin Immunol, 28, pp.187~196 (2016)
- Miao Y, "Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy", Cancer Biomark, 17, pp.33~40 (2016)
- Grivennikov SI, "Immunity, inflammation, and cancer", Cell, 140, pp.883~899 (2010)
- Tian C, "Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer : a meta-analysis", Eur J Clin Invest, 48, pp.e12917~ (2018)
- Huang QT, "Prognostic significance of neutrophil-tolymphocyte ratio in ovarian cancer : a systematic review and meta-analysis of observational studies", Cell Physiol Biochem, 41, pp.2411~2418 (2017)
- "NCCN clinical practice guidelines in oncology" (2019)[URL]
- Shan-Shan Li, "Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism", Journal of Gynecologic Oncology, 29(2), pp.1~11 (2018), 대한부인종양학회[DOI]